BioCryst Pharmaceuticals (NASDAQ:BCRX) now has an additional $2.5 million in funding it can apply toward its research into a treatment for Marburg virus disease.
The Durham company said that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option to conduct an investigational new drug-enabling program for the compound BCX4430 with the goal of filing an investigational new drug application with regulators.
NIAID, which is part of the National Institutes of Health, had granted an initial $5.0 million award to BioCryst in September. If all the options are exercised, the company stands to receive up to $22.0 million in funding over five years, which could advance the program through phase I clinical trials.
“This is an important next step in moving the development program forward to an IND submission, leading to an initial safety trial in healthy human volunteers,” BioCryst Chief Medical Officer Dr. William Sheridan said in a statement.
BCX4430 is an investigational compound that that has demonstrated broad-spectrum activity for multiple viruses
